ECHNO-ICHNO 2022 - The Joint International Congress on Innovative Approaches in Head and Neck Oncology and the European Congress on Head and Neck Oncology
Mar 03 - Mar 05, 2022 | BrusselsBelgium
LARVOL is not affiliated with The Joint International Congress on Innovative Approaches in Head and Neck Oncology and the European Congress on Head and Neck Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 10 abstracts linked to Trials
Results from CompARE phase III RCT: Dose Escalated Chemoradiation vs control in oropharyngeal cancer
Patient selection in the DAHANCA35 RCT of protons vs photons for H&N cancer
Durvalumab with cetuximab and radiotherapy for locally advanced HNSCC: a phase 1/2 trial
Why combining radiotherapy and IO is challenging
Hypofractionated vs standard radiotherapy in elderly unfit patients with HN cancer: ELAN-RT trial
Intensifying adjuvant therapy in advanced Oral Cavity Carcinoma: Results of a randomized study.
Volumetry to assess response to neoadjuvant chemotherapy in 2 prospective trials in sinonasal cancer
Harms and Quality of Life Results of the Dose Escalated Chemoradiation Arm in CompARE phase III RCT
ICIs in high risk oral potentially malignant lesions (IMPEDE study): an interim analysis on safety
A phase 2 study of serplulimab plus HLX07 in patients with advanced head and neck tumours